RFP: NCCN, Lilly for Abemaciclib (7.10.20)
The National Comprehensive Cancer Network® (NCCN®) is collaborating with Eli Lilly and Company, to offer an opportunity to support preclinical, clinical and correlative studies, as well as real world evidence evaluation, of abemaciclib in the management of breast cancer.
A Request for Proposals (RFP) clearly outlines the scope and process that will be followed for the submission of proposals.
The overall aim is to create innovative research and new knowledge in the area of de novo and acquired resistance to CDK 4 & 6 inhibitors. Proposals submitted in response to this RFP may assess predictive markers, and provide data useful in guiding further development of abemaciclib and novel rational combination therapies to overcome resistance to CDK 4 & 6 inhibitors.
Application Deadline: To be considered for funding, proposals must be submitted by 11:59 pm ET on Friday, July 10, 2020.
For more information: Please direct questions regarding this RFP to Nicole Kamienski at email@example.com with the subject line, “2020 Abemaciclib Project.”